Kentucky Trust Co Takes $1.67 Million Position in Pfizer Inc. (NYSE:PFE)

Kentucky Trust Co acquired a new stake in Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 62,791 shares of the biopharmaceutical company’s stock, valued at approximately $1,666,000.

Other institutional investors have also modified their holdings of the company. Exchange Traded Concepts LLC grew its holdings in Pfizer by 117.0% in the third quarter. Exchange Traded Concepts LLC now owns 69,178 shares of the biopharmaceutical company’s stock valued at $2,002,000 after purchasing an additional 37,293 shares during the period. Thurston Springer Miller Herd & Titak Inc. grew its holdings in Pfizer by 28.8% in the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 23,274 shares of the biopharmaceutical company’s stock valued at $674,000 after purchasing an additional 5,205 shares during the period. ORG Wealth Partners LLC purchased a new stake in Pfizer in the third quarter valued at approximately $115,000. Fiduciary Alliance LLC grew its holdings in Pfizer by 15.5% in the third quarter. Fiduciary Alliance LLC now owns 8,484 shares of the biopharmaceutical company’s stock valued at $246,000 after purchasing an additional 1,140 shares during the period. Finally, CX Institutional grew its holdings in Pfizer by 80.1% in the third quarter. CX Institutional now owns 46,207 shares of the biopharmaceutical company’s stock valued at $1,337,000 after purchasing an additional 20,552 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on PFE. Sanford C. Bernstein began coverage on shares of Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective for the company. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Wolfe Research began coverage on shares of Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. Citigroup decreased their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Trading Down 1.3 %

PFE opened at $25.53 on Wednesday. The stock has a market capitalization of $144.69 billion, a PE ratio of 18.11, a P/E/G ratio of 0.64 and a beta of 0.64. The firm’s fifty day moving average price is $26.28 and its 200 day moving average price is $27.69. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s quarterly revenue was up 24.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.10 earnings per share. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.74%. Pfizer’s dividend payout ratio is currently 121.99%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.